FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.
Microgen - stock.adobe.com
This article describes the data processing procedures and FDA statistical mathematics of an in-vitro permeation test (IVPT) study for evaluating a generic topical drug product against its reference product. IVPT-Stat v2.0, a tool composed of two Microsoft (MS) Excel files, is provided in the present paper to perform FDA statistic bioequivalence analysis with IVPT data (i.e., maximum flux [Jmax] and total cumulative amount permeated [denoted as AMT]) of the test and reference topical drug products. The algorithms and use of IVPT-Stat v2.0 are also elucidated with examples. As a MS Excel-based tool, IVPT-Stat v2.0 is user friendly and can be easily run by most industry practitioners and should make IVPT data analysis easy.
Click here for a PDF of this article.Click here for Table IV.Submitted: Feb. 17, 2023
Accepted: March 29, 2023
Lei Lei, PhD, ryan.lei@cutiatx.com, is the senior vice-president R&D of Cutia Therapeutics, Shanghai, China.
Article details
Pharmaceutical Technology
Vol, 47, No. 7
July 2023
Pages: 30–35
When referring to this article, please cite it as Lei, L. In-Vitro Permeation Test Data Analysis with MS Excel as per FDA’s Guidance. Pharmaceutical Technology 2023, 47 (7), 30–35.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.